Separately, a Phase I trial of GPC3 CAR-T cells incorporating IL-15 showed a 33% objective response rate and 66% stable disease rate in solid tumors, including HCC, with significantly enhanced T-cell expansion (573). Here, GPC3 is linked to hepatocellular carcinoma.